Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. is conducting a Phase 4 clinical study titled ‘A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventive Medications.’ The study aims to assess the effectiveness and safety of rimegepant, a drug intended to prevent migraines in adults who have not responded well to other oral preventive treatments.
The intervention being tested is rimegepant, administered as a 75 mg oral disintegrating tablet every other day. The study also includes a placebo group for comparison, ensuring robust results on the drug’s efficacy and tolerability.
This interventional study follows a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocations. The primary goal is to prevent migraines in the target population.
The study began on November 7, 2022, with an estimated completion date set for July 8, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might impact the market.
Pfizer’s update on this study could influence its stock performance positively, as successful results may enhance the company’s portfolio in migraine treatment. Investors should also consider the competitive landscape, as other pharmaceutical companies are actively developing migraine therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.